For Medical Doctors

AI supported interpretation of pulmonary function tests for a faster, easier and more accurate diagnostic process.

I use full PFT I use spirometry only

For Pharmaceutical Companies

ArtiQ’s Clinical Research portfolio leads to high-quality research data and efficient clinical trial workflows.

Instant AI-based over-reading for spirometry Risk based Monitoring to safe future data
Trusted Partners
Get the most out of your lung function data

Spirometry and other pulmonary function tests provide invaluable information about the lungs. However, there are also challenges in ensuring high-quality data and making a complete interpretation. ArtiQ develops software solutions that leverage the power of AI to support PFT interpretation and automate the assessment of spirometry quality.

Learn more about ArtiQ.PFT for interpretation support.

Discover ArtiQ.PFT

Learn more about ArtiQ.QC for automated spirometry quality assessment.

Discover ArtiQ.QC

Learn more about ArtiQ.RBM for AI-based risk monitoring.

Discover ArtiQ.RBM

Learn more about ArtiQ.Spiro for automated interpretation support for spirometry tests.

Discover ArtiQ.Spiro
Proven results

The ArtiQ technologies are profoundly tested and validated. These validations are published in key scientific journals and presented at international scientific and medical conferences. Get an overview of our scientific work and other relevant literature here.

Furthermore, ArtiQ is ISO 13585 certified and the ArtiQ.PFT solution is CE marked by an independent notified body according to the latest standards and medical device regulations.


I am convinced that ArtiQ.PFT is of utmost importance for the interpretation of pulmonary function in clinical practice as it gives a percentage value for different possible pathologies. It is better than the standard quick look of the pulmonologist and may save time.

Prof. Dr. Geert Verleden

Head of the Department of Respiratory Diseases, University Hospital Leuven

High-quality spirometry data is instrumental in respiratory research. ArtiQ.QC offers a reliable and complete evaluation of spirometry curves. The software can contribute to more successful respiratory clinical trials and increased reliability and enhanced validity of epidemiological studies where spirometry data is collected.

Dr. Sanja Stanojevic Epidemiologist,

Dalhousie University, Canada / Global Lung Function Initiative (GLI)

Through the Ai4SPIRO project, Chiesi and ArtiQ have proven that Artificial Intelligence can assess spirometry quality with high accuracy offering an alternative approach or assistance to over-reading. By providing immediate and consistent results, ArtiQ.QC may bring benefits to clinical trial conduct and reduce the variability in respiratory outcomes.

Isabella Montagna

Clinical Digital Leader – Chiesi Group

PFTs provide extensive numerical outputs, and their patterns need to be interpreted within a clinical context to come to a diagnosis. ArtiQ.PFT serves as a second opinion for us. The software is particularly helpful in recognizing rare but specific patterns.

Prof. Dr. Wim Janssens Adjunct Head

of Department of Respiratory Diseases, University Hospital Leuven

We have partnered with ArtiQ on multiple projects across obstructive and restrictive lung diseases. Their ArtiQ.QC product enables Koneksa and our sponsor partners to have confidence in the data that is being collected and enables real-time evaluation to ensure that patients are contributing high-quality pulmonary function tests remotely. This data, paired with ArtiQ’s RBM reports enables both patient-level and site-level intervention.

Matthew Cantor

Co-Founder, Koneksa

Digital health solutions and artificial intelligence are becoming key to optimising clinical trial design and delivery. The real-time feedback on spirometry that our partnership with ArtiQ brings, as well as their AI-enabled Risk Based Monitoring, helps AstraZeneca to increase the reliability of our data, allowing us to improve patient care and drive healthcare transformation.

Rod Hughes

Executive Medical Director, Early Respiratory and Immunology, AstraZeneca

Early identification and diagnosis of patients with COPD and other chronic respiratory diseases by spirometry is of utmost importance in the care pathway. Through the AISAH-COPD project, AstraZeneca and ArtiQ, have shown that ArtiQ.Spiro was useful for both quality assessment and diagnostic support in primary care. In addition, the use of AI led to the identification of undiagnosed COPD patients. I am convinced that the systematic use of ArtiQ.Spiro in primary care can increase the use of spirometry and may help to resolve the underdiagnosis of COPD and other chronic respiratory diseases.

Vincent Vanheule

Medical Affairs Manager at AstraZeneca